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Nottingham ( The association between the gradient to month 1, 3 and 6 and survival in the validation cohort are presented. The gradients are on the original linear scale and so the hazard ratio for these variables relates to the change in hazard for every unit increase in the slope. and 55 subjects with IPF represented by '■'. For ELM2 4% of values respectively were imputed. For all other epitopes the imputation rate was <1%. P values are provided where significant differences were observed between healthy subjects and IPF subjects.
Supplementary Figure 2: Pooled Analysis from the discovery and validation cohort of baseline neoepitope levels in healthy controls and IPF subjects with stable and progressive disease.
Combined numbers at baseline were 70 healthy subjects (•); 83 IPF subjects with stable disease (■) and 103 subjects with progressive IPF (▲). Three subjects for C3A and one for VICM were excluded due to missing baseline samples. Pooled biomarker data is presented as adjusted (least-squares) means (ng/ml) and 95% confidence intervals. These estimates were adjusted for age, cohort and age by cohort interaction. Disease progression was defined as all-cause mortality or ≥ 10% decline in FVC at 12 months. P values are presented where significant differences were observed between Healthy subjects and Stable IPF subjects (□); between healthy subjects and progressive IPF (∆) and between stable IPF and progressive IPF (◊). P values are based on the pair-wise comparison between groups, adjusted for age, cohort and age by cohort interaction. The pooled analysis shows that there is a significant difference between levels of C1M and C6M in stable IPF patients and healthy controls. Levels of BGM, C1M, C3M, C6M, CRPM and VICM are significantly higher in progressive IPF patients compared to controls. Between progressive and stable IPF patients, levels of C3A, C3M, C6M, CRPM and VICM are significantly increased.
Supplementary Figure 3: Sensitivity analysis for the comparison of neoepitope levels in healthy
controls and IPF subjects with stable and progressive disease at baseline and at 1, 3 and 6 months post baseline in the validation cohort. Disease progression was defined as all-cause mortality or ≥10% decline in FVC at 12 months. There were 16 cases without lung function data beyond baseline, so cases were adjudicated, following case note review, by the local principal investigator blinded to biomarker results. In the sensitivity analysis, these cases were removed leaving 50 IPF subjects with stable disease (■) and 65 subjects with progressive IPF (▲). Biomarker data represent means (ng/ml) and 95% confidence intervals, adjusted for age and gender. P values are provided where differences were observed between stable and progressive disease at a particular time point (◊).
This sensitivity analysis supports the original analysis ( Figure 3) by showing that levels of BGM, C1M, C3A, C3M, C6M and CRPM increase over time in the subjects with progressive, but not stable, disease.
Supplementary Figure 4: Kaplan-Meier plot showing overall survival for the PROFILE IPF cohort.
Curves are shown for the whole PROFILE IPF cohort of 189 subjects ( ) and are broken down in to those for the discovery ( ) (n=55) and validation cohorts ( ) (n=134). There was no significant difference in survival between cohorts. Mortality data were available for all subjects and were collected from the NHS registry with a date of censoring of 1 st October 2013.
